Drug intelligence / Profile preview

KINE-601A

Development stage: Preclinical
Lead developer: Kine Science
Modality: Peptides
Administration: Topical

Overview

KINE-601A is a therapeutic peptide candidate developed by Kine Science for the treatment of wounds and the promotion of tissue repair. Currently in the discovery or early preclinical stage, the drug is designed to modulate the biological activities of keratinocytes and fibroblasts, which are the primary cell types responsible for skin regeneration and the synthesis of the extracellular matrix. By targeting these key cellular components, KINE-601A aims to accelerate the natural healing process and improve the quality of tissue restoration in both acute and chronic wound settings.

Beyond the preview

Go deeper on KINE-601A.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on KINE-601A.

Explore the full profile